Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS

Bianca Weinstock-Guttman; Murali Ramanathan

doi:10.1038/nrneurol.2011.213

Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Multiple sclerosis research in 2011 produced a combination of new therapeutic developments and innovative findings. Teriflunomide showed beneficial effects in a phase III trial, quantification methods for MRI lesions that should improve monitoring of disease progression were devised, and a link between high cholesterol and low vitamin D emerged.

Original language	English
Pages (from-to)	66-68
Number of pages	3
Journal	Nature Reviews Neurology
Volume	8
Issue number	2
DOIs	https://doi.org/10.1038/nrneurol.2011.213
State	Published - Feb 2012

Access to Document

10.1038/nrneurol.2011.213

Cite this

@article{6d575f7df3844f30afaa16e3f5111f52,

title = "Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS",

abstract = "Multiple sclerosis research in 2011 produced a combination of new therapeutic developments and innovative findings. Teriflunomide showed beneficial effects in a phase III trial, quantification methods for MRI lesions that should improve monitoring of disease progression were devised, and a link between high cholesterol and low vitamin D emerged.",

author = "Bianca Weinstock-Guttman and Murali Ramanathan",

year = "2012",

month = feb,

doi = "10.1038/nrneurol.2011.213",

language = "English",

volume = "8",

pages = "66--68",

journal = "Nature Reviews Neurology",

issn = "1759-4758",

publisher = "Nature Research",

number = "2",

}

TY - JOUR

T1 - Multiple sclerosis in 2011

T2 - Advances in therapy, imaging and risk factors in MS

AU - Weinstock-Guttman, Bianca

AU - Ramanathan, Murali

PY - 2012/2

Y1 - 2012/2

N2 - Multiple sclerosis research in 2011 produced a combination of new therapeutic developments and innovative findings. Teriflunomide showed beneficial effects in a phase III trial, quantification methods for MRI lesions that should improve monitoring of disease progression were devised, and a link between high cholesterol and low vitamin D emerged.

AB - Multiple sclerosis research in 2011 produced a combination of new therapeutic developments and innovative findings. Teriflunomide showed beneficial effects in a phase III trial, quantification methods for MRI lesions that should improve monitoring of disease progression were devised, and a link between high cholesterol and low vitamin D emerged.

UR - https://www.scopus.com/pages/publications/84857054233

U2 - 10.1038/nrneurol.2011.213

DO - 10.1038/nrneurol.2011.213

M3 - Review article

C2 - 22231193

AN - SCOPUS:84857054233

SN - 1759-4758

VL - 8

SP - 66

EP - 68

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

IS - 2

ER -

Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS

Abstract

Access to Document

Other files and links

Fingerprint

Cite this